

Cardiovascular Risk Reduction in Patients with Diabetes:

New Opportunities and Options to Guide Your Practice

Friday, May 18, 2018

5:15 AM – 7:30 AM

CME Breakfast Symposium

Sheraton Boston Hotel

Grand Ballroom

39 Dalton St.

Boston, MA 02199



Faculty



Sergio Fazio, MD, PhD,
Chair



Deepak Bhatt, MD, MPH



Om Ganda, MD



Jorge Plutzky, MD

REGISTER ONLINE: AM.AACE.COM | Satellite Symposium #FSS1

This activity is provided by the American Association
of Clinical Endocrinologists.

Program management provided by Medtelligence.



This activity is supported by an educational grant
from Amarin Pharma Inc.

Cardiovascular Risk Reduction in Patients with Diabetes: New Opportunities and Options to Guide Your Practice

Program Overview

This interactive symposium will provide an opportunity for learners to evaluate the major changes recently developed on strategic considerations and clinical management of patients with type 2 diabetes at risk for CV events, including those with diabetic dyslipidemia. It will also highlight the potential clinical value of recent and emerging science and of large-scale randomized clinical trials on dyslipidemia and glucose-lowering, so learners will be able to discuss their potential clinical application.

Learning Objectives

After completing this activity, the participant should be better able to:

- Discuss the contribution of lipoproteins, inflammatory pathways, insulin resistance, and vascular cells in the formation of atherogenic plaques and eventual atherothrombosis
- Relate the clinical and genetic evidence for the association between elevated triglycerides/remnant lipoproteins and atherosclerosis
- Describe the anti-atherosclerotic/anti-inflammatory clinical results of therapies that have been shown to reduce atherosclerotic-based adverse events
- Apply evidence-based guidelines to lifestyle and therapeutic approaches for managing patients with elevated CV risk

Agenda

5:15 AM	Registration and Buffet Breakfast
5:45	Welcome and Program Overview <i>Sergio Fazio, MD, PhD, Chair</i>
5:55	Atherosclerotic Disease in Diabetes: Mechanistic Pathways and Therapeutic Interventions <i>Jorge Plutzky, MD</i>
6:15	Where Are We Now in Managing Non-HDL-C? <i>Deepak L. Bhatt, MD, MPH</i>
6:35	A New Era in CV Risk Reduction with Glucose-lowering Agents <i>Om P. Ganda, MD</i>
6:55	Clinician Live Discussion <i>All Faculty</i>
7:10	Challenging Cases for Discussion <i>Faculty and Attendees</i>
7:20	Q & A <i>All Faculty</i>
7:30 AM	Adjourn

Friday, May 18, 2018

Complimentary CME Breakfast Symposium

5:15 AM – 7:30 AM

Sheraton Boston Hotel

Grand Ballroom

39 Dalton St., Boston, MA 02199

Faculty



Sergio Fazio, MD, PhD, Chair

William and Sonja Connor Chair of Preventive Cardiology
Professor of Medicine, Physiology & Pharmacology
Director, Center for Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health & Science University
Portland, OR



Deepak L. Bhatt, MD, MPH

Executive Director, Interventional Cardiovascular Programs
Brigham and Women's Hospital Heart & Vascular Center
Professor of Medicine
Harvard Medical School
Boston, MA



Om P. Ganda, MD

Medical Director, Lipid Clinic
Chair, Clinical Oversight Committee
Associate Clinical Professor of Medicine
Harvard Medical School
Boston, MA



Jorge Plutzky, MD

Director, The Vascular Disease Prevention Program
Director, Preventive Cardiology
Brigham and Women's Hospital
Associate Professor, Harvard Medical School
Boston, MA

Needs Assessment Statement

A review of the literature, recent surveys, and conversations with experts on the treatment of diabetes reveals a number of important practice gaps, including a lack of familiarity and use of guideline recommendations and an unclear understanding of the treatment options for medical treatment of dyslipidemia and other CVD risk factors in the management of T2DM. There is a clear need to develop educational activities directed to physicians to discuss the current state of science, provide information on future potentially beneficial therapeutic targets, and simulate appropriate clinical approaches to managing blood glucose and CVD risk in patients with T2DM. Finally, there is a gap in understanding how the appropriate use of new agents might be effectively used in diabetes treatment plans.

Accreditation Statement

The American Association of Clinical Endocrinologists (AACE) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Association of Clinical Endocrinologists (AACE) designates this live activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medtelligence

2385 NW Executive Center Drive

Suite 100

Boca Raton, FL 33431

CME Breakfast Symposium

Cardiovascular Risk Reduction in Patients with Diabetes: *New Opportunities and Options to Guide Your Practice*

Friday, May 18, 2018

5:15 AM – 5:45 AM Registration and Buffet Breakfast

5:45 AM – 7:30 AM CME Symposium

Sheraton Boston Hotel

Grand Ballroom

39 Dalton St., Boston, MA 02199

Attendance Is Limited!

REGISTER TODAY: AM.AACE.COM

Use Satellite Symposium #FSS1

eSyllabus: Bring your personal device (laptop, etc) to the meeting, where WIFI access to the faculty slides will be available at: events.medtelligence.net/aace18f.html

Target Audience

Endocrinologists, Lipidologists, Internists, NPs/PAs, Diabetes Educators, Nurses, and other healthcare providers who care for patients with type 2 diabetes and patients with hyperlipidemia.